^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    PD-L1 expression

    i
    Other names: PD-L1, CD274, HPD-L1, PD-L1, B7H1, PDL1, Programmed death ligand 1, B7-H1, B7-H, PDCD1L1, PDCD1LG1, PDCD1 Ligand 1, B7 homolog 1, CD274 Antigen, Programmed cell death 1 ligand 1, CD274 molecule
    Entrez ID:
    29126
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    Related tests:
    1d
    KEYNOTE-E02: Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors (clinicaltrials.gov)
    P2, N=692, Recruiting, Seagen Inc. | Trial primary completion date: Apr 2025 --> Feb 2026
    Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • Tivdak (tisotumab vedotin-tftv)
    1d
    Comprehensive Genomic and Immune Profiling for the Detection of Clinically Significant Tumor Biomarkers (AMP 2024)
    Utilization of a multi-modal CGIP testing strategy resulted in a high rate of test success and detection of clinically relevant biomarkers and optimizing tissue usage.
    Clinical • Tumor mutational burden • IO Companion diagnostic • PD(L)-1 Biomarker • IO biomarker • PD(L)-1 companion diagnostic
    |
    PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability)
    |
    PD-L1 expression • TMB-H
    |
    TruSight Oncology 500 Assay • Oncomine™ Immune Response Research Assay
    1d
    A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study) (clinicaltrials.gov)
    P3, N=726, Not yet recruiting, mAbxience Research S.L.
    New P3 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • MB12 (pembrolizumab biosimilar)
    1d
    ARC-10: Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer (clinicaltrials.gov)
    P2, N=169, Active, not recruiting, Arcus Biosciences, Inc. | Phase classification: P3 --> P2 | Trial primary completion date: Aug 2024 --> May 2027
    Phase classification • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • PD-L1 overexpression
    |
    VENTANA PD-L1 (SP263) Assay
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel • pemetrexed • Yutuo (zimberelimab) • domvanalimab (AB154)
    3d
    Sincerely20: Sintilimab Combined With Chidamide in Treating Peripheral T Cell Lymphoma (clinicaltrials.gov)
    P2, N=51, Recruiting, Fudan University | Trial completion date: Sep 2025 --> Dec 2026 | Trial primary completion date: Dec 2023 --> Dec 2026
    Trial completion date • Trial primary completion date • IO biomarker • Epigenetic controller
    |
    PD-L1 expression
    |
    Tyvyt (sintilimab) • Epidaza (chidamide)
    4d
    A multicenter, single-arm clinical study of enlonstobart combined with chemoradiotherapy for locally advanced cervical cancer (ENLONG-003) (ChiCTR2400091264)
    P4, N=50, Not yet recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University of
    New P4 trial • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Avastin (bevacizumab) • cisplatin • carboplatin • paclitaxel • Enshuxing (enlonstobart)
    4d
    A multicenter, single-arm clinical study of enlonstobart combined with nab-paclitaxel and platinum drugs neoadjuvant therapy for locally advanced cervical cancer (ENLONG-001) (ChiCTR2400090024)
    P4, N=34, Not yet recruiting, Chinese PLA General Hospital; Chinese PLA General Hospital
    New P4 trial • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    cisplatin • carboplatin • albumin-bound paclitaxel • Enshuxing (enlonstobart)
    4d
    A multicenter, open-label, phase Ⅲ randomized controlled trial evaluating the efficacy and safety of adebrelimab in combination with chemotherapy and low-dose radiotherapy (LDRT) as first-line treatment for extensive-stage small cell lung cancer (SCLC) (ChiCTR2400090673)
    P3, N=202, Not yet recruiting, West China Hospital of Sichuan University; West China Hospital of Sichuan University
    New P3 trial • Combination therapy • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Ariely (adebrelimab)
    4d
    AK104 in combination with AK112 in an exploratory, multi-cohort stage II treatment of recurrent ovarian cancer study (ChiCTR2400090899)
    P2, N=172, Not yet recruiting, Fudan University Shanghai Cancer Center; Fudan University Shanghai Cancer Center
    New P2 trial • Combination therapy • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Kaitanni (cadonilimab) • Yidafan (ivonescimab)
    4d
    Maintenance therapy for high-risk locally advanced oral squamous cell carcinoma with PD-L1 positive after radical local therapy (ChiCTR2400089242)
    P2, N=21, Not yet recruiting, hunan cancer hospital; hunan cancer hospital
    New P2 trial • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    4d
    Locally advanced head and neck squamous carcinoma after radical treatment for high-risk patients, ripley's single joint capecitabine maintenance treatment of phase II clinical study (ChiCTR2400090080)
    P2, N=60, Recruiting, Tumor Hospital Affiliated to Guizhou Medical University; Tumor Hospital Affiliated to Guizhou Medical University
    New P2 trial • IO biomarker • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    capecitabine
    4d
    Phase I/ II clinical study of TAS-102 in combination with Fruquintinib and Sintilimab treat in patients with micro-satellite stable metastatic Colorectal cancer who have failed standard therapy (ChiCTR2400089944)
    P1/2, N=62, Recruiting, Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center
    New P1/2 trial • Combination therapy • IO biomarker • Metastases
    |
    PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability)
    |
    PD-L1 expression
    |
    Tyvyt (sintilimab) • Fruzaqla (fruquintinib) • Lonsurf (trifluridine/tipiracil)
    4d
    A Phase Ⅰ/II Clinical Study of SYS6010 in combination with Enlonstobart ± chemotherapy in patients with locally advanced or metastatic NSCLC and other advanced solid tumor (ChiCTR2400089402)
    P1/2, N=540, Not yet recruiting, Shanghai East Hospital; CSPC Megalith Biopharmaceutical Co., Ltd.
    New P1/2 trial • Combination therapy • Metastases
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    PD-L1 expression • EGFR mutation • ALK mutation • PD-L1 amplification
    |
    PD-L1 IHC 22C3 pharmDx
    |
    cisplatin • carboplatin • Enshuxing (enlonstobart)
    4d
    An exploratory clinical study to evaluate the safety, tolerability, and efficacy of low-dose radiotherapy (LDRT) and stereotactic radiotherapy (SBRT) combined with CAPEOX and tirellizumab in first-line treatment of HER2-negative advanced gastric cancer (ChiCTR2400089068)
    P1, N=36, Not yet recruiting, West China Hospital of Sichuan University; West China Hospital of Sichuan University
    New P1 trial • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden)
    |
    PD-L1 expression • HER-2 negative
    7d
    IMpassion132: A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer (clinicaltrials.gov)
    P3, N=595, Completed, Hoffmann-La Roche | Active, not recruiting --> Completed
    Trial completion • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Tecentriq (atezolizumab) • carboplatin • gemcitabine • capecitabine
    8d
    IMPRINTER: A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults with Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=24, Active, not recruiting, Imugene Limited | Trial completion date: Mar 2026 --> May 2025 | Trial primary completion date: Feb 2026 --> Nov 2024
    Trial completion date • Trial primary completion date • Combination therapy
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
    |
    PD-L1 expression
    |
    PD-L1 IHC 22C3 pharmDx • VENTANA PD-L1 (SP263) Assay • VENTANA PD-L1 (SP142) Assay
    |
    Tecentriq (atezolizumab) • IMU-201
    8d
    Fusobacterium nucleatum promotes PD-L1 expression in cancer cells to evade CD8+ T cell killing in breast cancer. (PubMed, Hum Immunol)
    Fn helps BC cells evade the killing effect of CD8+ T cells through the NF-κB/PD-L1 pathway.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • GZMB (Granzyme B) • RELA (RELA Proto-Oncogene)
    |
    PD-L1 expression • RELA expression
    8d
    Pooled Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone in Patients With Advanced Melanoma. (PubMed, J Clin Oncol)
    In this large, pooled nonrandomized retrospective analysis, we observed that NIVO + IPI provides longer OS than NIVO in patients with ICI treatment-naïve advanced melanoma and identifies clinical factors that appear to be associated with survival for each treatment, which may assist with treatment decision making.
    Journal • PD(L)-1 Biomarker • IO biomarker • Metastases
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene)
    |
    PD-L1 expression • BRAF mutation • BRAF wild-type • PD-L1-L
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    8d
    Isobutyric Acid Promotes Immune Evasion in Colorectal Cancer via Increased PD-L1 Expression. (PubMed, Cancer Med)
    Our study elucidates a novel mechanism by which IBA inhibits the sensitivity of CRC to anti-PD-L1 antibody therapy. Emphasizing IBA and its downstream pathways as potential therapeutic targets for immune therapy resistance mechanisms, our findings provide a novel theoretical foundation for overcoming immune therapy resistance.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CD8 (cluster of differentiation 8)
    |
    PD-L1 expression
    8d
    Exploratory analysis of immunomodulatory factors identifies L1CAM as a prognostic marker in alveolar soft-part sarcoma. (PubMed, Ther Adv Med Oncol)
    Immunomodulatory interventions may hold promise, as evidenced by PD-L1 expression and CD8+ infiltration. Further research, including larger cohorts and international collaborations, is needed to validate these findings and explore therapeutic strategies targeting L1CAM in ASPS.
    Journal • PD(L)-1 Biomarker • IO biomarker • Immunomodulating
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • FASLG (Fas ligand) • TFE3 (Transcription Factor Binding To IGHM Enhancer 3) • ASPSCR1 (ASPSCR1 Tether For SLC2A4) • L1CAM (L1 cell adhesion molecule)
    |
    PD-L1 expression • CD8-H • TFE3 fusion
    9d
    Network Medicine-Based Strategy Identifies Maprotiline as a Repurposable Drug by Inhibiting PD-L1 Expression via Targeting SPOP in Cancer. (PubMed, Adv Sci (Weinh))
    By applying Mnet-DRI to PD-L1, maprotiline (MAP), an antidepressant drug is repurposed, as a potential PD-L1 modifier for colorectal and lung cancers. Experimental validation revealed that MAP reduced PD-L1 expression by targeting E3 ubiquitin ligase speckle-type zinc finger structural protein (SPOP), and the combination of MAP and anti-CTLA4 in vivo significantly enhanced the antitumor effect, providing a new alternative for the clinical treatment of colorectal and lung cancer.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • SPOP (Speckle Type BTB/POZ Protein)
    |
    PD-L1 expression
    |
    maprotiline
    9d
    Mechanism of the KIAA1429/KLF1/PD-L1 Axis in Regulating Immune Escape in Non-small Cell Lung Cancer. (PubMed, Cell Biochem Biophys)
    Overexpression of KLF1 or PD-L1 reversed the immune-modulating effects of KIAA1429 knockdown. In conclusion, KIAA1429 facilitates immune evasion in NSCLC by stabilizing KLF1 mRNA and upregulating PD-L1 expression.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • IL2 (Interleukin 2) • IL10 (Interleukin 10) • VIRMA (Vir Like M6A Methyltransferase Associated)
    |
    PD-L1 expression • PD-L1 overexpression • IL10 elevation
    9d
    Comprehensive liquid biopsy analysis for monitoring NSCLC patients under second-line osimertinib treatment. (PubMed, Front Oncol)
    AXL and PIM-1 expression detected in CTCs during treatment suggesting new possible therapeutic strategies. Our results reveal that comprehensive liquid biopsy analysis can efficiently represent the heterogeneous molecular landscape and provide prominent information on subsequent treatments for NSCLC patients at PD since druggable molecular alterations were detected in CTCs.
    Journal • Liquid biopsy • PD(L)-1 Biomarker • IO biomarker • Biopsy
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • MET (MET proto-oncogene, receptor tyrosine kinase) • AXL (AXL Receptor Tyrosine Kinase) • B2M (Beta-2-microglobulin) • FOXA1 (Forkhead Box A1) • PIM1 (Pim-1 Proto-Oncogene) • VIM (Vimentin) • ALDH1A1 (Aldehyde Dehydrogenase 1 Family Member A1) • KRT19 (Keratin 19) • RASSF1 (Ras Association Domain Family Member 1) • WIF1 (WNT Inhibitory Factor 1) • BRMS1 (BRMS1 Transcriptional Repressor And Anoikis Regulator)
    |
    PD-L1 expression • BRAF V600E • KRAS mutation • EGFR mutation • KRAS G12C • HER-2 amplification • PIK3CA mutation • BRAF V600 • MET amplification • EGFR T790M • MET mutation • KRAS G12 • EGFR mutation + PIK3CA mutation • HER-2 amplification + PD-L1 expression • VIM expression • HER-2 amplification + MET amplification • RASSF1 methylation
    |
    Tagrisso (osimertinib)
    10d
    Personalized Vaccine Immunotherapy in Combination with Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer (clinicaltrials.gov)
    P1, N=18, Not yet recruiting, Emory University | Initiation date: Sep 2024 --> Dec 2024
    Trial initiation date • Combination therapy • Checkpoint inhibition • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    |
    PD-L1 expression • BRCA2 mutation • BRCA1 mutation • BRCA mutation
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Keytruda (pembrolizumab) • Yervoy (ipilimumab)
    10d
    Efficacy of rechallenge after first-line immunotherapy for advanced gastric cancer: A retrospective real-world study. (PubMed, Hum Vaccin Immunother)
    Rechallenge after first-line immunotherapy showed good survival benefit and acceptable safety in the therapy of AGC. Especially for patients with HER-2-positive and PD-L1 CPS ≥ 1%, rechallenge may be an effective treatment modality.
    Retrospective data • Journal • Real-world evidence • Real-world • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • HER-2 positive
    10d
    ACE2 Enhances Sensitivity to PD-L1 Blockade by Inhibiting Macrophage-Induced Immunosuppression and Angiogenesis. (PubMed, Cancer Res)
    Pharmacological targeting of CCR5 using maraviroc enhanced the tumor suppressive effect of anti-PD-L1 therapy. Together, these findings suggest that activation of the ACE2 axis overcomes the immunosuppressive microenvironment of HCC and may serve as an immunotherapeutic target and predictive biomarker of response to PD-L1 blockade.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CCL5 (Chemokine (C-C motif) ligand 5) • ACE2 (Angiotensin Converting Enzyme 2)
    |
    PD-L1 expression • PD-L1 overexpression
    |
    Selzentry (maraviroc)
    10d
    Targeting PLCG2 Suppresses Tumor Progression, Orchestrates the Tumor Immune Microenvironment and Potentiates Immune Checkpoint Blockade Therapy for Colorectal Cancer. (PubMed, Int J Biol Sci)
    Meanwhile, knockdown of PLCG2 could potentiate the efficacy of ICB therapy. In summary, we have identified for the first time that PLCG2 could be considered a precise biomarker and promising therapeutic target for predicting CRC prognosis, optimizing individualized treatment, reversing CRC immune escape, and overcoming resistance to ICB therapy.
    Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker • Checkpoint block
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • PLCG2 (Phospholipase C Gamma 2)
    |
    PD-L1 expression • PD-1 expression
    10d
    Prognostic and therapeutic potential of gene profiles related to tertiary lymphoid structures in colorectal cancer. (PubMed, PeerJ)
    Key genes in our model, including C5AR1, APOE, CYR1P1, and SPP1, were implicated in COADREAD cell proliferation, invasion, and PD-L1 expression. These insights offer a novel approach to colorectal carcinoma treatment, emphasizing TLS targeting as a potential anti-tumor strategy.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • SPP1 (Secreted Phosphoprotein 1) • APOE (Apolipoprotein E)
    |
    PD-L1 expression
    10d
    Noninvasive Monitoring of Programmed Death-Ligand 2 Expression with Positron Emission Tomography using 68Ga-labeled Peptide Antagonist in Preclinical and Exploratory Human Studies. (PubMed, Research (Wash D C))
    The results indicate a higher response rate to anti-PD-1 therapy in patients positive for both PD-L1 and PD-L2, with PD-L2 status independently predicting progression-free survival (PFS) with pembrolizumab treatment. Furthermore, [68Ga]Ga-HN11-1 PET imaging demonstrates specificity in assessing PD-L2 status. Overall, we confirm the correlation between high PD-L2 expression and favorable PFS in NSCLC patients post anti-PD-1 therapy and highlight the promising potential of [68Ga]Ga-HN11-1 as a specific tracer for PD-L2 in preclinical and initial human trials.
    Preclinical • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L2 (Programmed Cell Death 1 Ligand 2)
    |
    PD-L1 expression • PD-L1 negative • PD-L2 expression
    |
    Keytruda (pembrolizumab)
    10d
    PD-1/PD-L1 and coronary heart disease: a mendelian randomization study. (PubMed, Front Cardiovasc Med)
    GSEA found that the KEGG pathway and related core genes of "PD-L1 expression and PD-1 checkpoint pathway in cancer" pathway were downregulated in CHD. This study provided evidence of a bidirectional causal relationship between PD-1 and chronic ischemic heart disease and a protective association between chronic ischemic heart disease and PD-L1.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
    |
    PD-L1 expression
    10d
    A PD-L1-Targeted Probe Cy5.5-A11 for In Vivo Imaging of Multiple Tumors. (PubMed, ACS Omega)
    Moreover, the fluorescent signal of A11-Cy5.5 in the xenografts was successfully blocked by coinjection of unlabeled A11 peptide or knockdown of cellular PD-L1 by shRNA, indicating the specificity of Cy5.5-A11 targeting PD-L1 in tumor imaging. Our data demonstrate that Cy5.5-A11 is a novel tool for tumor imaging of PD-L1, which has the potential for detecting cancer and predicting ICI therapeutic responses.
    Preclinical • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • ANXA1 (Annexin A1)
    |
    PD-L1 expression
    10d
    Heterogeneity between subgroups of first-line chemoimmunotherapy for extensive-stage small cell lung cancer patients: a meta-analysis and systematic review. (PubMed, Front Oncol)
    More trials are needed to prospectively validate the therapeutic heterogeneity among clinicopathological characteristics. https://inplasy.com/inplasy-2023-3-0064/ identifier, INPLASY202330064.
    Retrospective data • Review • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • PD-L1 negative
    10d
    Lymphocytic Esophagitis Associated With Chronic Severe Psoriasis: A Case Report With Special Reference to Programmed Death-Ligand 1 Expression. (PubMed, Cureus)
    We present a new case of LE associated with chronic severe psoriasis, highlighting the role of PD-L1 expression. This supports the immunopathological basis of the disease and its links to other immune and autoimmune disorders, suggesting its potential as a biomarker for distinguishing LE from reflux esophagitis.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
    |
    PD-L1 expression
    10d
    NCI-2018-02050: Nivolumab and Temozolomide in Treating Patients with Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer (clinicaltrials.gov)
    P2, N=55, Active, not recruiting, Dwight Owen | Trial primary completion date: Jul 2024 --> Dec 2024
    Trial primary completion date • Tumor mutational burden • Metastases
    |
    PD-L1 expression
    |
    Opdivo (nivolumab) • temozolomide
    11d
    Camrelizumab combined with gemcitabine and apatinib in treating advanced PD-L1-positive biliary tract cancers. (PubMed, Cancer Sci)
    The most frequent grade 3 or 4 treatment-related adverse event was neutropenia (n = 4, 29%). The combination of camrelizumab, gemcitabine, and apatinib showed promising efficacy and acceptable safety in patients with advanced PD-L1-positive biliary tract cancer.
    Journal • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    gemcitabine • AiRuiKa (camrelizumab) • AiTan (rivoceranib)
    11d
    SKYSCRAPER-09: A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov)
    P2, N=123, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Oct 2024 --> Feb 2025
    Trial completion date • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Tecentriq (atezolizumab) • tiragolumab (RG6058)
    11d
    MT-6402-001: Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1 (clinicaltrials.gov)
    P1, N=64, Terminated, Molecular Templates, Inc. | N=138 --> 64 | Active, not recruiting --> Terminated; Terminated by Sponsor
    Enrollment change • Trial termination • IO biomarker • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    MT-6402
    11d
    neoMono: Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy with Atezolizumab - CTX Therapy (clinicaltrials.gov)
    P2, N=416, Completed, Palleos Healthcare GmbH | Active, not recruiting --> Completed
    Trial completion
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    PD-L1 expression • HER-2 negative • ER negative • PGR negative
    |
    VENTANA PD-L1 (SP142) Assay
    |
    Tecentriq (atezolizumab) • carboplatin • paclitaxel • cyclophosphamide • epirubicin
    11d
    NCI-2018-00192: Pembrolizumab and Sunitinib Malate in Treating Participants with Refractory Metastatic or Unresectable Thymic Cancer (clinicaltrials.gov)
    P2, N=30, Recruiting, Dwight Owen | Suspended --> Recruiting
    Enrollment open • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Keytruda (pembrolizumab) • sunitinib
    11d
    Highly-Multiplexed Immunofluorescence PhenoCycler Panel for Murine FFPE Yields Insight into Tumor Microenvironment Immunoengineering. (PubMed, Lab Invest)
    Delivery of IFNγ, in addition to 4-1BBL and IL-12, further increased markers of antigen presentation on tumor cells and intratumoral antigen-presenting cells but also promoted greater expression of checkpoint marker PD-L1 and closer associations between intratumoral CD8 T cells and PD-L1-expressing tumor cells. These findings help to explain the benefits of 4-1BBL and IL-12 delivery while offering additional mechanistic insights into the limitations of IFNγ therapeutic efficacy.
    Preclinical • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma)
    |
    PD-L1 expression • CD8 expression
    11d
    Durvalumab Following Chemoradiotherapy for Stage III Non-small Cell Lung Cancer: Differences in Survival Based on Age and Post-Progression Systemic Therapy. (PubMed, Target Oncol)
    In the studied cohort, OS was significantly shorter for patients ≥ 75 years of age treated with cCRT followed by durvalumab compared to those < 65 years. Post-progression systemic therapy was associated with modest efficacy, underscoring the need for new therapies.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Imfinzi (durvalumab)
    12d
    Echinacoside inhibits tumor immune evasion by downregulating inducible PD-L1 and reshaping tumor immune landscape in breast and colorectal cancer. (PubMed, Phytomedicine)
    ECH upregulates the expression of inducible PD-L1 through the JAK/STAT1/IRF1 signaling pathway, enhances T cell function, and reshapes the tumor immune landscape into an anti-tumor phenotype. Importantly, ECH markedly enhances the efficacy of ICB treatment, indicating its potential application in anti-tumor therapy.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CD4 (CD4 Molecule)
    |
    PD-L1 expression • IFNG expression • IRF1 expression